CELLULITES CERVICO-FACIALES EXTENSIVES ET ANTI-INFLAMMATOIRES NON STEROIDIENS

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

PHARMACOLOGIE DE L'ACETONIDE DE TRIAMCINOLONE (NASACORT*) UTILISE EN PULVERISATIONS NASALES DANS UN SERVICE D'O.R.L;

REIMS-BU Santé (514542104) / SudocSudocFranceF

Aspects comparatifs anatomo-radiologiques de la partie inférieure de la paroi laterale de la fosse nasale chez des adultes avec et sans larmoiement

REIMS-BU Santé (514542104) / SudocSudocFranceF

La sarcoïdose nasosinusienne

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Les carcinomes épidermoïdes du sinus maxillaire

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Prise en charge de la pathologie infectieuse du sinus sphénoïdal. Revue de la littérature et présentation de 9 cas cliniques au C.H.U. de Reims

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

LES TUMEURS DE LA PAROTIDE (NOTRE ATTITUDE THERAPEUTIQUE ; A PROPOS DE 185 CAS)

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Prise en charge par le médecin généraliste des pathologies dentaires

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Assessment of peak inspiratory flow in the management of acute inspiratory dyspnoea

International audienc

Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy

International audienceAims: To investigate the predictive capacity of early post-treatment diffusion-weightedmagnetic resonance imaging (MRI) for recurrence or tumor progression in patients with no tumorresidue after chemo-radiotherapy (CRT) for head and neck squamous cell carcinoma, and, to assessthe predictive capacity of pre-treatment diffusion-weighted MRI for persistent tumor residuepost-CRT. Materials and Method: A single center cohort study was performed in one Frenchhospital. All patients with squamous cell carcinoma receiving CRT (no surgical indication) wereincluded. Two diffusion-weighted MRI were performed: one within 8 days before CRT and one 3months after completing CRT with determination of median tumor apparent diffusion coefficient(ADC). Main outcome: The primary endpoint was progression-free survival. Results: 59 patientswere included prior to CRT and 46 (78.0%) completed CRT. A post-CRT tumor residue was foundin 19/46 (41.3%) patients. In univariate analysis, initial ADC was significantly lower in patients withresidue post CRT (0.56 ± 0.11 versus 0.79 ± 0.13; p < 0.001). When initial ADC was dichotomizedat the median, initial ADC lower than 0.7 was significantly more frequent in patients with residue postCRT (73.7% versus 11.1%, p < 0.0001). In multivariate analysis, only initial ADC lower than 0.7 wassignificantly associated with tumor residue (OR = 22.6; IC [4.9–103.6], p < 0.0001). Among 26 patientswithout tumor residue after CRT and followed up until 12 months, 6 (23.1%) presented recurrence orprogression. Only univariate analysis was performed due to a small number of events. The only factorsignificantly associated with disease progression or early recurrence was the delta ADC (p = 0.0009).When ADC variation was dichotomized at the median, patients with ADC variation greater than 0.7had time of disease-free survival significantly longer than patients with ADC variation lower than 0.7(377.5 [286–402] days versus 253 [198–370], p < 0.0001). Conclusion and relevance: Diffusion-weightedMRI could be a technique that enables differentiation of patients with high potential for early recurrencefor whom intensive post-CRT monitoring is mandatory. Prospective studies with more inclusionswould be necessary to validate our results